Infliximab therapy modulates an antigen-specific immune response in chronic beryllium disease
- PMID: 22974830
- PMCID: PMC4347848
- DOI: 10.1016/j.rmed.2012.08.014
Infliximab therapy modulates an antigen-specific immune response in chronic beryllium disease
Conflict of interest statement
Drs. Lisa A. Maier, Lee S. Newman, and Milt Rossman have received research grants from Centocor to support this work. As part of this grant Juliana Barnard and May Gillespie received support to conduct the work for this project. Drs. Lisa Maier and Milton Rossman also direct beryllium testing laboratories and have provided consultation in patient related medicolegal issues.
References
-
- Henneberger PKG, Sandra K, Miller William E, Doney Brent, Groce Dennis W. Industries in the United States with airborne beryllium exposure and estimates of the number of current workers potentially exposed. J Occup Environ Hyg. 2004;1:648–59. - PubMed
-
- Samuel GM, Lisa A. Immunology of chronic beryllium disease. Curr Opin Allergy Clin Immunol. 2008;8:126–34. - PubMed
-
- Schuler CRK, Michael S, Deubner David C, Berakis Michael T, McCawley Michael, Henneberger Paul K, Rossman Milton D, Kreiss Kathleen. Process-related risk of beryllium sensitization and disease in a copper–beryllium alloy facility. Am J Ind Med. 2005;47:195–205. - PubMed
-
- Henneberger PKC Debra, Deubner David D, Kent Michael S, McCawley Michael, Kreiss Kathleen. Beryllium sensitization and disease among long-term and short-term workers in a beryllium ceramics plant. Int Arch Occup Environ Health. 2001;74:167–76. - PubMed
-
- Daniloff EMB, Bucher Becki, Newell John D, Jr, Bernstein Steven M, Newman Lee S. Observer variation and relationship of computed tomography to severity of beryllium disease. Am J Respir Crit Care Med. 1997;155:2047–56. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
